Taxotere gets fast track status for head and neck cancer indication

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 8
Volume 16
Issue 8

Taxotere gets fast track status for head and neck cancer indication

BRIDGEWATER, New Jersey—Sanofi-aventis has received priority review from the FDA for its supplemental New Drug Application for Taxotere (docetaxel) in combination with cisplatin and fluorouracil for induction (neoadjuvant) therapy of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) prior to chemoradiotherapy and surgery. The combination is currently approved for induction therapy of inoperable advanced SCCHN. The submission is based on the TAX 324 phase III study showing significantly improved overall survival in patients treated with the Taxotere combination vs cisplatin/fluorouracil alone.

Articles in this issue
Avoiding copay shock
Induction chemo increases survival in unresectable NSCLC
Superselective chemo strategies for HCC
'Value meal dosing' of lapatinib is proposed
AMA approves CPT code for Axxent electronic brachytherapy
Zevalin/R after CHOP-R doubles CRs in follicular NHL
Active surveillance with delayed treatment appears to be a safe option for younger men with low-risk prostate cancer
RT plus local paclitaxel gel promising in esophageal ca
GeneSearch BLN Assay gets FDA approval for node assessment during surgery
TH vs TCH in metastatic breast cancer: 'Take your pick'
Sunitinib prolongs PFS in RCC: update
Diagnostic Dilemma: GI Disease
ACS studies link patients' insurance status to cancer outcomes
Novel MAGE-A3 immunotherapeutic promising as adjuvant therapy of early-stage non-small-cell lung ca
US consumers are shielded from the cost of healthcare
Related Videos
Treatment with toripalimab does not yield the same vascular toxicity seen with pembrolizumab in patients with advanced or metastatic nasopharyngeal carcinoma, according to Barbara Burtness, MD.
Overall survival also appears to improve with toripalimab compared with chemotherapy among patients with metastatic or advanced nasopharyngeal carcinoma.
head and neck cancer
head and neck cancer
head and neck cancer
Related Content
FDA Gives Fast Track Designation to LYT-200 in Advanced Head and Neck Cancers

FDA Gives Fast Track Designation to LYT-200 in Advanced Head and Neck Cancers

April 12th 2024
Article

LYT-200 is currently being investigated for those with solid tumors and hematologic malignancies.

David Sher on the Updated ASTRO Guidelines for Oropharyngeal Cancer

David Sher on the Updated ASTRO Guidelines for Oropharyngeal Cancer

September 15th 2017
Podcast

In this interview we discuss new clinical guidelines from ASTRO on the use of radiotherapy in treating oropharyngeal cancer.

Radiation Therapy Plus Chemo Yielded Increased Efficacy in HPV+ Oropharynx Cancer

Radiation Therapy Plus Chemo Yielded Increased Efficacy in HPV+ Oropharynx Cancer

March 4th 2024
Article

The use of postoperative adjuvant radiation therapy led to less weight loss in patients with HPV-positive oropharynx cancer, according to Wade L. Thorstad, MD.

Frontline pembrolizumab with or without chemotherapy appears to remain a standard of care for patients with recurrent or metastatic head and neck squamous cell carcinoma based on data from the LEAP-010 study.

Pembrolizumab/Lenvatinib Combo Shows Mixed Results in Recurrent/Metastatic HNSCC

March 1st 2024
Article

Frontline pembrolizumab with or without chemotherapy appears to remain a standard of care for patients with recurrent or metastatic head and neck squamous cell carcinoma based on data from the LEAP-010 study.

The FDA grants clearance to an oral immobilization stent designed to redirect radiation to the target tumor area for patients with head and neck cancer.

FDA Clears Oral Stent Solution for Radiotherapy in Head and Neck Cancer

January 22nd 2024
Article

The FDA grants clearance to an oral immobilization stent designed to redirect radiation to the target tumor area for patients with head and neck cancer.

After observing a prevalence of thyroid cancer among transgender female patients through clinical observation, a study was prompted by clinicians in order to determine if this is an issue in a larger population.

Thyroid Cancer Rates Are Higher Among Transgender Female Veterans

October 29th 2023
Article

Study shows a high prevalence of thyroid cancer in transgender female patients.